Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Marlotamig - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Marlotamig - Regeneron Pharmaceuticals

Alternative Names: Anti-EGFRxCD28 bispecific antibody - Regeneron Pharmaceuticals; REGN-7075

Latest Information Update: 26 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 15 Dec 2025 Regeneron pharmaceutical plans a phase II trial for Rectal cancer (Late-stage disease, Combination therapy, Neoadjuvant therapy) in USA (IV) (NCT07281768)
  • 04 Sep 2025 Regeneron Pharmaceuticals plans a phase II trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in January 2026 (NCT07154290)
  • 10 Oct 2024 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (IV) (NCT06465329)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top